February 9, 2023: Dr. Diana Zuckerman of NCHR urges the FDA Oncology Advisory Committee to require randomized trials of Jemperli for rectal cancer instead of single arm trials, so that patients and physicians can make informed decisions about the best treatment.
Read More »On Medical Treatments & Products
NCHR Comments on the CDC proposed new Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children
January 27, 2023: Hepatitis C infections have dramatically increased among pregnant women, which exposes babies during birth. National Center for Health Research supports CDC’s recommendations for HCV testing of all infants and children born to pregnant mothers with confirmed or probable HCV.
Read More »NCHR Comments on the FDA Preliminary Assessment of Potential Non-prescription Naloxone Products
January 17, 2023: NCHR agrees with the FDA’s assessment that certain types of naloxone drug products could be safe and effective for non-prescription use but training is needed to use it correctly in urgent situations. We also support FDA’s request for more research to determine how to provide the most effective instructions and labeling for non-prescription naloxone products.
Read More »NCHR Comments on the Consumer Product Safety Commission’s Proposed Ruling of Safety Standards for Adult Portable Bed Rails
January 9, 2023: NCHR strongly agrees with CPSC’s proposed ruling that APBR has an “unreasonable risk of injury and death associated with entrapment hazards” and enthusiastically supports CPSC’s plan to make the voluntary safety standards mandatory, include new requirements for testing and labeling, and consider banning the products if the new standards do not substantially improve their safety. It is important to consider alternatives to APBR’s if it becomes necessary to ban them, and alternatives can be bed trapezes, adjustable beds, nonslip mattress pads, and bed exit alarms.
Read More »NCHR Testifies Before Cardiovascular and Renal Drugs Advisory Committee on Heart Failure Drug
Dr. Ealena Callender of National Center for Health Research tells Dec. 2022 FDA Advisory Committee to require better research on OM heart failure drug due to lack of evidence of efficacy and concerns about safety due to toxicity.
Read More »